Psoriasis vaccine - Astralis/Pacira

Drug Profile

Psoriasis vaccine - Astralis/Pacira

Alternative Names: AS 210; Psoraxine; Second-generation Psoraxine

Latest Information Update: 11 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astralis
  • Class Antipsoriatics; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Psoriasis

Most Recent Events

  • 11 Dec 2007 Suspended - Phase-II for Psoriasis in USA (Injection)
  • 22 Jun 2007 SkyePharma Inc. is now called Pacira Pharmaceuticals
  • 06 May 2005 Data presented at the 66th Annual Meeting of the Society for Investigative Dermatology (SID-2005) have been added to the adverse events and Skin Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top